title: [Analysis of weekly paclitaxel chemotherapy for esophageal cancer].
abstract: OBJECTIVE
  Public knowledge-based application for paclitaxe(l PAC) has been approved for advanced or recurrent esophageal cancer. We investigated the feasibility of weekly PAC chemotherapy as a second-line or subsequent regimen for metastatic or recurrent esophageal cancer.
  
  
  METHODS
  Patients received PAC( 100 mg/m2 intravenously) on days 1, 8, 15, 22, 29, and 36 of each 8-week period. We analyzed the toxicity and efficacy in 6 patients treated with the weekly PAC chemotherapy.
  
  
  RESULTS
  Grade 3-4 toxicities were neutropenia, leukopenia, and anemia. Two patients had stable disease and 2 had progressive disease.
  
  
  CONCLUSIONS
  By managing the side effects, weekly PAC therapy is considered a feasible regimen that can be administered on an outpatient basis.
authors.affiliation: Dept. of Surgery, Osaka General Medical Center.
authors.forename: Junji
authors.initials: J
authors.lastname: Kawada
authors.forename: Masashige
authors.initials: M
authors.lastname: Nishimura
authors.forename: Yuki
authors.initials: Y
authors.lastname: Matsui
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Nomura
authors.forename: Yuki
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Okumura
authors.forename: Katsuki
authors.initials: K
authors.lastname: Danno
authors.forename: Masaru
authors.initials: M
authors.lastname: Kubota
authors.forename: Chu
authors.initials: C
authors.lastname: Matsuda
authors.forename: Kenichi
authors.initials: K
authors.lastname: Omori
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Masaya
authors.initials: M
authors.lastname: Nomura
authors.forename: Mari
authors.initials: M
authors.lastname: Takagi
authors.forename: Akiko
authors.initials: A
authors.lastname: Fukui
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Fujitani
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwase
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel